Applications of N-[3-Chloro-4-(3-Fluorobenzyloxy)Phenyl]-6-Iodoquinazolin-4-Amine in Industrial Manufacturing

N-[3-Chloro-4-(3-Fluorobenzyloxy)Phenyl]-6-Iodoquinazolin-4-Amine serves as a high-value advanced intermediate in several regulated downstream sectors, where strict compliance to industry norms and technical precision determine its adoption. Our material supports scale-up synthesis with validated consistency to facilitate customers’ process development, stringent quality demands, and final product registrations.

1. Active Pharmaceutical Ingredient (API) Synthesis for Oncology Small Molecules

This compound is employed as a targeted synthetic intermediate in the assembly of next-generation kinase inhibitor APIs for oncological indications. Its inclusion enables the final coupling steps before purification and formulation, directly influencing the consistency of drug substance manufacture. Downstream pharmaceutical clients require strict adherence to global regulatory norms to qualify these advanced intermediates for new-drug filings.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• 21 CFR Part 210/211 U.S. cGMP regulation for finished pharmaceuticals
• EU GMP Volume 4 Part 2 (APIs)
• Traceability expectations for advanced intermediates in NDA/ANDA registration submissions

Typical usage ratio

• Stoichiometric use: 1.0–1.2 molar equivalents per target oncology API batch; scale adjusted for stepwise conversion yields and impurity limits

Downstream process integration

• Introduced during the penultimate heterocyclic condensation or selective amination step, followed by recrystallization and chromatographic purification before formulation

Final product types

• Small-molecule kinase inhibitor APIs targeting solid tumors (e.g., EGFR, ALK inhibitors)
• Bulk pharmaceutical ingredients for oncology therapies

2. Chemical Reference Standard Synthesis for Pharmaceutical Quality Control

Regulated analytical laboratories and pharmaceutical manufacturers utilize this intermediate as a building block for preparing traceable chemical reference standards. These standards support method validation, impurity profiling, and long-term stability studies for both in-house and regulatory submissions, requiring the use of highly characterized and audited synthesis pathways.

Industry compliance standards

• ISO 17034:2016 for reference material producers
• USP <1058> Analytical Instrument Qualification
• Ph. Eur./USP/JP monograph requirements for impurity standards
• OECD Good Laboratory Practice principles

Typical usage ratio

• Constitutes 0.05–0.5% (w/w) of total analytical batch formulation; ratio adapted to calibration curve span and matrix concentration

Downstream process integration

• Forms the final synthetic fragment in multi-step reference material production, with subsequent HPLC/MS or NMR quantification, certificate assignment, and ampoule filling

Final product types

• Chemical reference standards for API release testing
• Certified impurity markers for drug product QC laboratories

3. Targeted Crop Protection Intermediate in Advanced Agrochemical Synthesis

In the crop protection sector, this quinazoline derivative functions as a highly specific intermediate for the controlled synthesis of novel herbicidal actives. Its molecular structure allows for selective functionalization and integration into proprietary formulations, and its use is governed by agricultural chemistry regulatory frameworks.

Industry compliance standards

• FAO/WHO Specifications for Plant Protection Products
• REACH registration requirements for agrochemical actives
• ISO 17025 Laboratory Accreditation for agrochemical batch analysis
• OECD Test Guidelines for pesticide development

Typical usage ratio

• Reactive intermediate: 1.1–1.3 equivalents introduced per final active moiety; optimized to minimize processing waste and maximize product purity

Downstream process integration

• Employed in the late-stage coupling or substitution step before crude active isolation and post-reaction neutralization

Final product types

• Novel herbicidal actives for broadleaf and grass weed management
• Pre-mix technical concentrates for large-scale farm applications

4. Specialty Chemical Intermediate for Diagnostic Reagent Manufacture

Manufacturers in the clinical diagnostics field incorporate this compound as a custom intermediate in the development of enzymatic and bioluminescent substrate kits. The molecular features enable conjugation to proprietary probes, and the production process requires careful attention to residual solvents and contaminants that influence diagnostic specificity.

Industry compliance standards

• ISO 13485:2016 for in vitro diagnostic manufacturing
• EU IVDR 2017/746 compliance for diagnostic reagents
• FDA 21 CFR 820 Quality System Regulation for Medical Devices
• CLSI guidelines for reagent batch release

Typical usage ratio

• Used at 0.1–0.8 equivalents per probe conjugation step; actual proportion determined by target substrate specificity and detection sensitivity thresholds

Downstream process integration

• Added during the molecular probe assembly or linker functionalization phase, followed by ultrafiltration or chromatography prior to formulation into reagent kits

Final product types

• Diagnostic substrate solutions for immunoassay platforms
• Custom enzyme/conjugate kits for hospital laboratory systems